Results 61 to 70 of about 18,490 (188)

Nectin4‐targeted molecular imaging in solid tumors: Current status and future perspectives

VIEW, EarlyView.
In this review, we provide a concise overview of the mechanisms by which Nectin4 contributes to the pathogenesis of various malignancies and detail the classes of Nectin4‐targeted molecular probes. We then delve into the significant advancements in Nectin4‐targeted molecular imaging techniques, encompassing both nuclear medicine and optical imaging ...
Yongshun Liu, Wenpeng Huang, Jingwei Zhou, Rachel J. Saladin, Youlan Lei, Weibo Cai, Lei Kang   +6 more
wiley   +1 more source

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX‐622

Allergy, EarlyView.
SCF and TSLP expression are known to drive unique immune responses leading to the onset of allergic and inflammatory diseases. Here, we describe the characterization of a novel bsAb, CDX‐622, that targets SCF and TSLP. CDX‐622 inhibits MC functions through SCF starvation and Type 2 inflammatory responses via TSLP inhibition.
Michael B. Murphy, Laura Vitale, Thomas O'Neill, Deena M. Maurer, Linda Malenchek, Andrea Crocker, Colleen Patterson, Laura Mills‐Chen, Virginia Saley, Nicole M. Antczak, James M. Boyer, Kelly M. McManus, Noe Rico Montanari, Russell A. Hammond, Joel Goldstein, Lawrence J. Thomas, Tibor Keler, Diego Alvarado   +17 more
wiley   +1 more source

Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

British Journal of Haematology, EarlyView.
Summary Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3 ...
Sean McKeague, Molly Robertson, Sam van der Linde, Christine Khoo, Jonathan Segal, Sean Harrop, Adrian Minson, Andrew W. Roberts, Michael Dickinson   +8 more
wiley   +1 more source

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non‐Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group

British Journal of Haematology, EarlyView.
Summary Developing new therapeutic regimens for relapsed/refractory (R/R) B non‐Hodgkin lymphoma (NHL) patients remains a significant unmet clinical need. Our objective was to evaluate atezolizumab (ATE), obinutuzumab (OBI) and venetoclax (VEN) combination in patients with R/R NHL who had received at least one prior anti‐CD20‐containing ...
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Pierre Feugier, Gandhi Damaj, Hervé Tilly, Loïc Ysebaert, Steven Le Gouill, Nadine Morineau, Emmanuel Gyan, Rémy Gressin, Roch Houot, Morgane Cheminant, Franck Morschhauser, Catherine Thieblemont, Corinne Haioun, Emmanuelle Nicolas‐Virelizier, Luc‐Matthieu Fornecker, Nicolas Daguindau, Guillaume Cartron   +21 more
wiley   +1 more source

The role of blinatumomab in adult acute B lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Blinatumomab, a CD19‐directed bispecific T‐cell engager, has become a crucial part of BCP‐ALL therapy in r/r disease, MRD‐positive disease and has recently been implemented into first‐line therapy of BCP‐ALL. This review discusses important clinical trials with a focus on blinatumomab in first‐line therapy of adult BCP‐ALL.
Anne C. Wilke, Nicola Gökbuget
wiley   +1 more source

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

The dark sides of the GPCR tree ‐ research progress on understudied GPCRs

British Journal of Pharmacology, EarlyView.
Abstract A large portion of the human GPCRome is still in the dark and understudied, consisting even of entire subfamilies of GPCRs such as odorant receptors, class A and C orphans, adhesion GPCRs, Frizzleds and taste receptors. However, it is undeniable that these GPCRs bring an untapped therapeutic potential that should be explored further.
Magdalena M. Scharf, Laura J. Humphrys, Sandra Berndt, Antonella Di Pizio, Juliane Lehmann, Ines Liebscher, Alessandro Nicoli, Masha Y. Niv, Lior Peri, Hannes Schihada, Gunnar Schulte   +10 more
wiley   +1 more source

Composite Lymphoma: A Rare Case of Vomiting

United European Gastroenterology Journal, EarlyView.
Changqin Liu, Dongyan Han, Xiaomin Sun
wiley   +1 more source

Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial

Cancer Science, EarlyView.
In this multicenter, single‐arm, open‐label phase II trial, patients with HER2‐positive breast cancer who had previously received chemotherapy with taxanes or anthracyclines were enrolled to receive pyrotinib combined with nab‐paclitaxel, and the results demonstrated promising efficacy with an acceptable safety profile.
Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing, Zhichao Gao, Hui Cao, Fangyuan Dong, Jie Wu, Cui Jiang, Yangyang Duan, Xiaorui Li, Yujun Jiang, Lei Jiang, Ying E, Yufeng Jia, Liang Zhang, Pai Peng, Tao Sun   +23 more
wiley   +1 more source

Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR‐SCREEN‐2 Study

Cancer Science, EarlyView.
ABSTRACT Claudin 18.2 (CLDN18.2), a tight junction protein isoform, is an emerging therapeutic target in oncology. CLDN18 is well‐characterized in gastric cancer, but its pan‐cancer expression profiles and isoform distributions are poorly documented.
Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, Norio Nonomura, Chigusa Morizane, Hiroji Iwata, Susumu Okano, Wataru Yamagami, Naoya Yamazaki, Shigenori Kadowaki, Makoto Ueno, Shogen Boku, Eiji Oki, Yoshito Komatsu, Satoshi Yuki, Akitaka Makiyama, Takatsugu Ogata, Naoki Takahashi, Naohiro Okano, Tomohiro Nishina, Naoya Sakamoto, Takeshi Kuwata, Riu Yamashita, Taro Shibuki, Mitsuho Imai, Takao Fujisawa, Hideaki Bando, Kohei Shitara, Takayuki Yoshino   +28 more
wiley   +1 more source